All In Biotech

NDA 020126 · Mylan

Zonalon

Doxepin Hydrochloride · Topical

Last checked: Nov 19, 2026Latest source record: Dec 20, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Apr 1, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

19

4 Phase 3, 3 recruiting

FAERS reports

2,131

1,398 serious, 349 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 29, 2017.

INDICATIONS AND USAGE PRUDOXIN ® Cream is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. (See DOSAGE AND ADMINISTRATION .)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 1, 1994 Original approval · Type 3 - New Dosage Form
1 products under this application
  • ZONALON · DOXEPIN HYDROCHLORIDE 5% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxepin" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain206
  • drug ineffective192
  • completed suicide188
  • dizziness169
  • insomnia165
  • fall156
  • toxicity to various agents156
  • fatigue152
  • anxiety142
  • pruritus136
  • off label use132
  • product use in unapproved indication125

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200423
200539
200646
200718
200815
200925
201029
201122
201245
201345
201416
201531
201655
201767
201868
2019164
2020159
2021170
2022142
2023151
2024250
2025320
2026231

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zonalon (Doxepin HCl)

2024 spending

$12K

Beneficiaries

n/a

13 claims

Per beneficiary

n/a

$16.00 per unit

View as table
YearSpending
2020$641,915
2021$30,502
2022$40,624
2023$18,743
2024$11,998

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 310 on PubMed

Sponsor: Mylan

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.